A plain language summary of results from the CHRYSALIS study
Preliminary data from the CHRYSALIS study suggests that amivantamab may hold promise in NSCLC treatment for EGFR exon 20 insertion mutation patients. View the video summary of the study above.
Creator: Kristian Baycroft-Willmott
The opinions expressed in this interview are those of the author and do not necessarily reflect the views of Oncology Central or Future Science Group.
In association with Janssen Oncology
